secwatch.observer — SEC 8-K summary
======================================

Issuer:     FATE THERAPEUTICS INC (FATE)
CIK:        0001434316
Form:       8-K
Filed at:   2022-06-13T23:59:59+00:00
Accession:  0000950170-22-011554
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fate Therapeutics shareholders approve 2022 Stock Plan, elect all director nominees
--------------------------------------------------------------------------------

- Stockholders approved 2022 Stock Option and Incentive Plan with 61.5M for, 23.2M against, 84.7K abstain.
- Class III directors Coughlin, Wolchko, and Agarwal elected; Agarwal received 69.7M for, 15.0M withheld.
- Ratification of Ernst & Young as auditor for FY2022 passed with 90.1M for, 69K against.
- Non-binding advisory vote on executive compensation passed with 75.4M for, 9.1M against.
- Broker non-votes of 5.5M shares on director election, say-on-pay, and plan approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434316/000095017022011554/0000950170-22-011554-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434316/000095017022011554/fate-20220609.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-011554

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer